A new formulation developed by University of South Australia scientists to treat antimicrobial-resistant bacterial infections in diabetic foot ulcers could also be used to kill the COVID-19 virus ...

New England Journal of Medicine Evidence Publishes Results of the Largest Randomized Controlled Trial of its Kind ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kerecis, the pioneer in the use ...

Performing proactive surgery to adjust the mechanics of the foot, appears to be effective to treat diabetic foot ulcers, a common and debilitating complication of diabetes, without the potential ...

The photo of the patient's foot, sent from his campsite, included a cheeky note: "I remember you telling me that getting in trouble doing something was better than getting in trouble doing nothing.

POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of ...

High-density lipoprotein, otherwise known as good cholesterol, may be a promising topical treatment for diabetic foot ulcers (DFUs) and other challenging wounds, according to an Australian study ...

Researchers have isolated phages from zoo-dwelling lemurs, giraffes, binturongs, Visayan pigs and Guinea baboons that might help fight diabetic foot ulcers. University of Sheffield Foot ulcers are a ...

A Southeast Missouri doctor is taking advantage of stem-cell technology to treat his patients' wounds and getting results faster than any treatment he's used in the past. Last year, Dr. Hugh Protzel ...

The proportion of wounds healed at 16 weeks was higher with intact fish skin grafts than with standard-of-care (44.0% vs 26.4% adjusted odds ratio [aOR], 2.58; 95% CI, 1.48-4.56). The fish skin grafts ...

Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biopharmaceutical company focused on cellular energy restoration therapeutics, today announced it will present clinical application ...

ATLANTA, Aug. 3, 2017 /PRNewswire/ -- VM BioPharma, the United States division of ViroMed Co., Ltd. in Seoul, Korea (KOSDAQ: 084990), today announced the first patient was dosed in the recently ...

Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biopharmaceutical company focused on cellular energy restoration therapeutics, today announced ...